Magenta Therapeutics, Inc.
MGTA · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,633.7% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,362.8% | – | – | – |
| EPS Diluted | -21.75 | -23.05 | -1.12 | -1.43 |
| % Growth | 5.6% | -1,958% | 21.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |